Protagonist Therapeutics, Inc. is a biotech company developing new medicines.
Protagonist Therapeutics, Inc. (PTGX) is expected to report earnings on Thursday, November 5, 2026, after the close. Estimated release time 16:10 ET. Consensus EPS estimate is $2.43.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-05 | FY2026 Q2 | $2.27 | $2.47 | +8.8% | $213.47M |
| 2026-05-05 | FY2026 Q1 | $-0.65 | $0.06 | +108.9% | — |
| 2026-02-25 | FY2025 Q4 | $-0.53 | $-0.69 | -30.2% | $7.44M |
| 2025-08-06 | FY2025 Q2 | $-0.53 | $-0.55 | -3.8% | $5.55M |
| 2025-05-06 | FY2025 Q1 | $-0.50 | $-0.19 | +62.0% | — |
| 2025-02-21 | FY2024 Q4 | $0.06 | $2.11 | +3416.7% | $170.64M |
| 2024-08-06 | FY2024 Q2 | $-0.50 | $-0.50 | +0.0% | $4.17M |
| 2024-05-07 | FY2024 Q1 | $1.19 | $3.41 | +186.6% | $254.95M |
PTGX has beaten consensus EPS in 6 of its last 8 reported quarters.
Highlights from PTGX's Aug 5 report: EPS of $2.47 — a beat vs the $2.27 estimate (+9%); revenue of $213M — in line with the $212M consensus.
See PTGX on the live calendar →